Synthesis and characterization of pH-sensitive drinkable nanoparticles for oral delivery of ibuprofen

• Published in: Nanotechnology 2018-06, Vol.29 (22), p.225604
• Main Authors: Agostini, Azzurra, Capasso Palmiero, Umberto, Barbieri, Sara D A, Lupi, Monica, Moscatelli, Davide
• Format: Article
• Language: English
• Subjects: Administration, Oral; Cell Death - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; controlled release; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; ibuprofen; Ibuprofen - administration & dosage; Ibuprofen - chemistry; Ibuprofen - pharmacology; Nanoparticles - chemistry; Nanoparticles - toxicity; Nanoparticles - ultrastructure; pH-sensitive; polymeric nanoparticles; Polymers - chemical synthesis; Polymers - chemistry; Proton Magnetic Resonance Spectroscopy; Spectrophotometry, Ultraviolet
• ISSN: 0957-4484; 1361-6528
• DOI: 10.1088/1361-6528/aab536

Ibuprofen (IBU) is a widespread drug used to treat both acute and chronic disorders. It is generally taken orally but the free drug can induce the irritation of the gastric mucosa due to its acid nature. In literature, different approaches have been adopted to prevent the release in the stomach, such as physical entrapment with film-coated tablets and drug-conjugates. Nevertheless, these solutions have many disadvantages, including the fast release of the drug and the difficulty to swallow the tablet, especially for children who may vomit or refuse the tablet. For this reason, in this work, novel formulations are proposed that do not require the encapsulation of the drug into a solid form and, in turn, their assumption as a pill. IBU has been linked to different types of methacrylates via ester bond in order to produce pH-responsive macromolecular monomers. The novelty is related to the use of these drug-conjugates macromonomer for the production of nanoparticles (NPs) via emulsion polymerization (EP), using water as solvent. The final emulsion is able to load up to 30 mg ml−1 of IBU, so less than 10 ml is required to be assumed to reach the minimum therapeutic dose of the drug (200 mg). Finally, the release of IBU from these novel drinkable formulations has been investigated in the gastric and intestinal simulated fluids to show the preferential release of IBU from the NPs in basic conditions. A comparison with an existing oral suspension has been performed to highlight the slower release in acid environment of these new formulations. Afterwards, the IBU loaded NPs were tested in vitro showing lower toxicity compared to the free drug.